5 Houston biotech companies taking health care to new levels

The future is now

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.

Concession food to your seat? Sign InnovationMap readers up. Courtesy of sEATz

5 top trending innovation stories in Houston this week

What you're reading

Editor's note: Not entirely surprisingly, this week's views were skewed heavily toward an app that allows stadium food delivery right to your seat, wine-picking technology, a slideshow of a growing coworking space, and more.

Houston startup is making stadium food a whole new ballgame

A new app, sEATz, is the UberEats of stadium food. You order right from your phone in your seat. Getty Images

Marshall Law's wife, Melissa, surprised him and his two sons with tickets to see the Astros play at home in the 2017 World Series against the Los Angeles Dodgers, but a rush to get to the game and a packed stadium lead to him waiting in a long concessions line in the second inning.

Law watched on a TV screen next to the food counter as the fourth pitch from Yu Darvish to Yuli Gurriel hit two rows past the Laws' seats, bouncing back toward where they were supposed to be sitting. Law couldn't shake the feeling of missing out on the homer. Why couldn't someone have brought them the food, he thought. He'd have paid $50 — maybe more — to not miss that moment.

"Everything gets delivered these days. Any kind of food to your groceries, all right to you. Why isn't someone doing this?" Law says he was thought as he walked out of the game. Read the full story here.

Photos: West Houston coworking space 50 percent leased ahead of early 2019 opening

The Cannon's 120,000-square-foot space is on track to open March 1. Courtesy of The Cannon

Everything's bigger in Texas, and Houston will soon have a coworking space to reflect that. The Cannon is on track to open its West Houston 120,000-square-foot, 32-acre coworking and entrepreneurship campus by March 1.

"We're going to have, as far as I know, the biggest coworking space in the world," says Lawson Gow, founder and CEO of The Cannon. "It's a really Houston-sized solution to the problem of the challenge we set out to face." Read the full story here.

3 Houston health tech innovators to know this week

Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

Whether it's for dogs or dating, Houston is prime for innovative leaders in health science startups, and there are three in particular you need to know going into a new week. From a DNA-based dating app creator and a researcher curing cancer in dogs to cutting-edge biotech leader, here are the Houston innovators to know. Doctorate degrees and startup companies in hand, each of these entrepreneurs is going places. Read the full story here.

Houston company aims to equally equip female workers

SeeHerWork launched its line of female-gear in September. Courtesy of SeeHerWork

When Jane Henry was working on her home right after Hurricane Harvey — her house got three feet of mud in it — she went to throw a board into the dumpster, and her glove went with it.

Henry says the industry standard is to recommend small and extra-small sizes for women's workwear, but as a ladies large in athletic gloves, Henry still had a good inch or so of glove at her fingertips in her workwear gloves.

"I went upstairs to my sewing room, and I ripped that glove apart and I resewed it to fit my hand," Henry says. Read the full story here.

Houston entrepreneur makes a splash with wine-selecting technology

Houston-based VineSleuth created a custom algorithm to match you with new wines based on wines you've had in the past. Courtesy of VineSleuth

Amy Gross wants to find you the perfect wine. In fact, she wants it so much, she built her company, VineSleuth, around the concept that technology and machine learning could find the best wine to match individual palates.

VineSleuth's custom algorithm is backed by research from sensory scientists at Cornell University, and relies on both data collection and machine learning to determine specific wines that will match an individual customer's tastes. Flavor profiles from thousands of wines are incorporated into her database, and none of those are based on the typical wine scores you'll see in magazines or reviews of wines. Read the full story here.

Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

3 Houston heath tech innovators to know this week

Who's Who

Brittany Barreto, co-founder and CEO of Pheramor

Courtesy of Pheramor

Brittany Barreto was studying genetics in college, and her professor was talking about how there are 11 genes in DNA that can determine physical compatibility with others. She had the idea right then and there in the classroom to make a DNA-based dating app. Almost 10 years later, she's done it, with Pheramor.

The Houston startup has launched nationwide and is in the midst of another capital campaign. Barreto is also looking to expand her team to account for the growth and success.

Lidong Qin, founder of Innovative Biochips

Courtesy of Lidong Qin

Lidong Qin spends his days as a professor at the Houston Methodist Research Institute's department of nanomedicine, but three years ago, he expanded his resume. He launched his biotech startup, Innovative Biochips, as an independent faculty startup that licensed technology from Houston Methodist.

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers. Now, iBiochips is armed with private investments and a $1.5 million grant from the National Institutes of Health's Small Business Technology Transfer program to continue researching and developing early disease detection technologies.

Colleen O'Connor, founder of CAVU Biotherapies

Courtesy of CAVU Biotherapies

Losing a pet is awful, and for so many people, pets are full-blown family members. When Colleen O'Connor lost her furry family members to cancer, she knew she had to do something about it. Cancer treatment in humans had evolved to include immunotherapy, and O'Connor thought man's best friend deserved an upgrade from the 1980s practices veterinarians use.

She created Houston-based CAVU Biotherapies, and, in September, the first treatment was administered to a black lab named Franklin. O'Connor is focused on expanding her treatment and its access to pups so that no pet owner has to prematurely say goodbye to good boys and girls.

iBiochips was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Getty Images

Houston-based biotech company aims to revolutionize cellular dissection technology

digital disease detective

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers.

"In the Houston area, even though it looks like it's a lot of state money (grants) around, it's very limited, and that's been a challenge of ours," Qin says.

But with the help of a $1.5 million investment from a private investor, Qin was able to launch iBiochips in 2015, and shortly after opened his own lab on Kirby Drive.

Recently, iBiochips was awarded a $1.5 million grant in September from the National Institutes of Health's Small Business Technology Transfer program. The grant will further support the company's research and development of an automated yeast dissection chip, which is designed to perform a raw analysis of single cells and deliver data about the cell's genetic makeup and report abnormalities.

Prior to the phase two grant, iBiochips was also awarded NIH's phase one grant of $225,000 in September 2017 to develop a prototype for the company's flagship cell isolation product, the Smart Aliquotor.

The Smart Aliquotor is a single-cell isolation dissection platform that allows scientists to analyze larger amounts of cells at a much faster rate than traditional isolation methods, Qin says. He says the system is also more convenient for researchers to operate because traditional cell isolation techniques require a lot of human effort.

To isolate the cells with a Smart Aliquotor, a scientist would take a patient's blood sample and inject it into a single point in the device. The blood sample would then travel through microfluidic channels into the device's 60 to 100 isolated holes, Qin says.

"In three days, we can handle about one million cells," Qin says. "In a traditional approach, people can handle only one or two cells in three days. So that is how we came to the [idea of the] chip can help a scientist do 20 years of work in three days."

The Smart Aliquotor can then be examined with iBiochips' newly funded automated dissection chip, which Qin says has the potential to detect cancer or infectious diseases earlier than before.

"If you isolate a cell by itself — even in the very beginning stage when the aggressive cells are not as dominating yet — you can still see that [abnormality in the sample]," Qin says.

iBiochips' products are currently only being manufactured for research use at clinical labs, universities and pharmacies. However, with the recent grant award, Qin says the company's research team plans to spend the next three to five years preparing the products for worldwide commercialization.

Dr. Lidong Qin is a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist.Courtesy of Lidong Qin

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Axiom Space expands executive team with two C-suite hires

new leaders

Fresh off officially making Texas its legal headquarters, Axiom Space has named two new C-level executives.

The Houston-based spacetech company, which is developing the first commercial space station, announced earlier this month that it had appointed Zach Gitomer as its new chief financial officer and Erick Wegerer as chief information officer.

Gitomer served as vice president of investor relations and capital markets for Axiom from March to June of this year. Before joining Axiom, he held various leadership roles at Bank of America, Merrill Lynch, and Citi, where he supported technology and growth companies, according to Axiom.

"Building era-defining space infrastructure and pioneering the orbital economy is a complex endeavor that requires not just an audacious vision and stellar engineering talent, but the financial infrastructure, discipline, and capital strategy to match," Gitomer shared in a LinkedIn post. "I’m honored to take on this role ... I’m looking forward to partnering with the exceptional leadership team here at Axiom Space during a defining chapter for the company and commercial spaceflight broadly, as well as a crucial period for maintaining U.S. human presence in low-Earth orbit and leadership in space exploration."

Wegerer joins Axiom after most recently serving as CIO of Washington-based Insitu Inc., a subsidiary of Boeing that develops customized unmanned hardware for commercial, government and defense customers.

"My time at Insitu was defined by talented people, meaningful challenges, and work that mattered. I'm grateful for the teams, partners, and leaders who made progress there possible. Stepping into Axiom, I'm energized by the mission, the momentum, and the opportunity to help shape what's next," Wegerer shared.

Photo via LinkedIn

The duo was celebrated on the floor of the New York Stock Exchange last week.

“We are pleased to welcome these exceptional leaders to the Axiom Space team," Axiom CEO Jonathan Cirtain added in the announcement. “Their strong record of helping complex organizations advance their strategic priorities will strengthen our executive team to further advance our core business objectives."

It's been a busy summer for Axiom. The company tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million, in June.

It also announced plans to open a Japanese subsidiary July 1. It tapped veteran Japanese astronaut Koichi Wakata to lead Axiom Space Japan as chief technology officer in the Asia-Pacific region. It also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

Axiom also officially redomiciled its legal headquarters from Delaware to Texas last month. Read more here.

Houston hardtech accelerator names 8 founders to 2026 cohort

hardtech fellows

Hardtech-focused organization Activate has named 50 new members to its 2026 cohort of scientists, which includes eight startups joining Activate Houston.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

This year's fellows represent 41 companies from 22 U.S. cities and 11 states.

“This cohort clearly demonstrates that the next industry-defining companies won't choose between modern technology and deep science; they'll be built by combining both,” Cyrus Wadia, CEO of Activate, said in the announcement. “These are the scientists and engineers turning our most urgent global challenges into the companies that will deliver a more sustainable future.”

The Houston fellows are working across the energy, space, AI infrastructure and agriculture sectors. They include:

Sophie Clare Broun, founder of Anning Corporation, which is producing clean hydrogen by stimulating naturally occurring geologic deposits
Kathy Andersen, founder of Brint Tech, which builds optical sensing systems that quantify hydrogen for infrastructure operators
Dorsa Talebi, founder of Kinetiq Drive, which builds rare-earth-free, contact-free electric motors with wireless rotors for small appliances and heavy industry alike
Neethu Pottackal, founder of Nivera, which is developing natural, edible coatings made from agricultural byproducts to reduce food waste and extend the shelf life of fresh food
Jonathan Huffman, founder of Orbital Arc, which is shrinking spacecraft propulsion to a microchip powerful enough for deep space
Tim Lee, founder of Renesin, which develops advanced materials for faster, more efficient AI hardware
Joshua Livingston, founder of Selerra Separations, which is developing high-performance membranes that cut the cost and energy consumption of water treatment
Wenli Jiang, founder of SwieNitro Recovery, which is developing technology that converts nitrogen-rich waste streams into valuable fertilizer

"Home to the largest concentration of engineers in the United States and a dense ecosystem of Fortune 100 and Fortune 500 companies, Houston is uniquely positioned for scientists tackling large-scale industrial challenges. Activate Houston fellows are connected to the city's deep networks in energy, chemicals, and materials," Activate said in the announcement.

Activate named its inaugural Houston cohort in 2024. It has other hubs in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Nationally, it has supported 346 fellows and 276 companies since 2015.

Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion. The latest cohort is Activate Houston's third. Read more about the last year's cohort here.

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME